ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Year: 2024
Type: article
Source: Clinical Cancer Research
Authors: Ross A. Soo, Urania Dafni, Ji-Youn Han, Byoung Chul Cho, Ernest Nadal, Chong Ming Yeo, Enric Carcereny, Javier de Castro, Maria Angeles Sala, Linda Coate, Mariano Provencio, Christian Britschgi, Patrick Vagenknecht, Georgia Dimopoulou, Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, for the ETOP 10-16 BOOSTER Collaborators
Institutions: National University Cancer Institute, Singapore, National and Kapodistrian University of Athens, Frontier Science Foundation-Hellas, National Cancer Center, Yonsei University, Yonsei Cancer Hospital, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Tan Tock Seng Hospital, Hospital Universitario La Paz, Hospital de Basurto, University Hospital Limerick, Hospital Universitario Puerta de Hierro Majadahonda, University of Zurich, Kantonsspital Winterthur, University Hospital Zurich, International Breast Cancer Study Group, Trinity College Dublin, St. James's Hospital, Centre Hospitalier Universitaire Vaudois, University of Lausanne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: ETOP IBCSG Partners Foundation
OpenAlex ID: W4402350809